InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

(2020) Athena Philis-Tsimikas et al.   DIABETOLOGIA

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018

(2019) Nicole C. Foster et al.   Diabetes Technology & Therapeutics

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

(2019) Tadej Battelino et al.   DIABETES CARE

Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study

(2019) Jeremy H. Pettus et al.   DIABETES CARE

Assessing Glucose Trend Accuracy with a Novel Continuous Glucose Monitoring System

(2018) TERRI JOHNSON et al.   DIABETES

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

(2018) T.S. Bailey et al.   DIABETES & METABOLISM

Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Degludec in Patients with Type 2 Diabetes: A Randomized, Open-Label, Crossover Study Using Continuous Glucose Monitoring Profiles

(2018) Yuji Kawaguchi et al.   Journal of Diabetes Investigation

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized crossover study

(2018) Mizuho Yamabe et al.   Journal of Diabetes Investigation

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

(2018) Julio Rosenstock et al.   DIABETES CARE

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1

(2016)   DIABETES CARE

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes

(2016) Louis Monnier et al.   DIABETES CARE

Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review

(2016) Pamela Martyn-Nemeth et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial

(2016) Jan Bolinder et al.   LANCET

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

(2014) Hanne Haahr et al.   CLINICAL PHARMACOKINETICS

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview

(2013) David M. Nathan et al.   DIABETES CARE